The reactions of [(CFSOCu)(CH)] with the sterically hindered imidazolin-2-imine ligands DippImTMS (1,3-Bis(2,6-diisopropylphenyl)-2-(trimethylsilylimino)imidazoline) or DippImH (1,3-bis(2,6-diisopropylphenyl) imidazolin-2-imine) lead to the formation of the linear copper(I) complexes [Cu(DippImTMS)(OTf)] () and [Cu(DippImH)][OTf] (), respectively. The triflate counteranion in can be easily exchanged to the weakly coordinating [BAr] giving [Cu(DippImH)][BAr] () (BAr = tetrakis[3,5-bis(trifluoromethyl)phenyl]borate). Substitution of the N-heterocyclic imine (NHI) ligand in by AlCp* (Cp* = pentamethylcyclopentadienyl) gives the tetrahedral [Cu(AlCp*)][BAr] ().
View Article and Find Full Text PDFReaction of neutral olefin complexes of ruthenium and molybdenum with GaTMP (TMP = 2,2,6,6-tetramethylpiperidinyl) by substitution leads to the formation of respective five- and six-coordinated homoleptic products. [Ru(GaTMP)] (1) and [Mo(GaTMP)] (2) were isolated and characterized. Core structure geometries were analyzed using continuous shape measure, and the complexes were subjected to DFT calculations unveiling competing π-interactions between the transition metal center and the amido substituent with the unoccupied p orbitals of the gallium.
View Article and Find Full Text PDFPurpose: To evaluate a computer-based prior authorization system that was designed to include and test two new concepts for physician review: (1) the tool would minimize denials by providing real-time decision support with alternative options if the original request was noncompliant, and (2) the tool would collect sufficient information to create a patient registry.
Methods: A new prior authorization tool incorporating real-time decision support was tested with a large national payer. The tool used the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as the content for decision making.